Chandigarh May 24, 2024:- A patent has been granted to Panjab University, Chandigarh by The Patent Office, Government of India for an invention entitled “A two-component lantibiotic roseocin from Streptomyces filamentosus NRRL 11379” for the term of 20 years from the 8thday of June 2018 in accordance with the provisions of the Patents Act,1970.The inventors are Prof. Dipti Sareen and Dr. Mangal Singh of Department of Biochemistry, Panjab University, Chandigarh.

Importance of the patent:

To challenge the global threat of AMR (antimicrobial resistance), ‘lantibiotics’ are emerging as the promising drugs against multi drug resistant bacteria. The World Health Organization (WHO) has identified antibiotic resistance to be one of the biggest threats to global health. To counter antibiotic resistance, the WHO has recommended research and development of new antimicrobial agents as one of the major objectives in The Global Action Plan on Antimicrobial Resistance (2015).The inventors of the present invention have developed a novel antibacterial lantibiotic, Roseocin. This peptide-based drug can be used for inhibiting growth of drug resistant bacteria.The patent is on a process of biosynthesis of the lantibiotic, Roseocin, througha genetically engineered expression system enabling the independent production of fully modified and matured two components of this lantibiotic in E. coli host strain. This expression system is an important cornerstone for the ongoing bioengineering studies and is of significance for potential applications aiming at higher production titers of the antibacterial peptide-based drug, Roseocin.